QuidelOrtho (NASDAQ:QDEL) Announces Earnings Results, Misses Expectations By $0.44 EPS

QuidelOrtho (NASDAQ:QDEL) posted its quarterly earnings data on Wednesday. The company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.44), Zacks reports. QuidelOrtho had a negative net margin of 66.25% and a positive return on equity of 4.24%. QuidelOrtho updated its FY 2025 guidance to 2.070-2.570 EPS.

QuidelOrtho Stock Down 3.7 %

Shares of QDEL stock traded down $1.53 on Wednesday, reaching $39.94. 1,309,639 shares of the company were exchanged, compared to its average volume of 889,851. The company has a market cap of $2.69 billion, a price-to-earnings ratio of -1.43 and a beta of 0.08. The company has a 50-day moving average of $43.28 and a 200-day moving average of $42.36. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.38 and a quick ratio of 0.81. QuidelOrtho has a one year low of $29.74 and a one year high of $68.85.

Analysts Set New Price Targets

A number of analysts have commented on QDEL shares. StockNews.com raised shares of QuidelOrtho from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. William Blair reaffirmed a “market perform” rating on shares of QuidelOrtho in a research report on Wednesday, November 20th. Citigroup raised shares of QuidelOrtho from a “neutral” rating to a “buy” rating and upped their price target for the company from $44.00 to $50.00 in a research report on Wednesday, December 11th. Finally, Jefferies Financial Group started coverage on shares of QuidelOrtho in a research report on Tuesday, December 10th. They set a “hold” rating and a $43.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $53.43.

Insider Transactions at QuidelOrtho

In other QuidelOrtho news, CEO Brian J. Blaser purchased 6,033 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were acquired at an average price of $41.42 per share, with a total value of $249,886.86. Following the transaction, the chief executive officer now owns 6,033 shares in the company, valued at $249,886.86. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the firm’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $35.31, for a total transaction of $291,667,061.73. The disclosure for this sale can be found here. Insiders own 1.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.